Af­ter steer­ing Lund­beck through buy­outs, lay­offs and big ap­proval, Deb­o­rah Dun­sire will step down

Last year
People

Look­ing to ex­pand Pyrukynd la­bel, Agios treks to­ward PhI­II in sick­le cell dis­ease

Last year
R&D

Lon­za, Ver­tex to build a new cell ther­a­py man­u­fac­tur­ing fa­cil­i­ty for the biotech’s type 1 di­a­betes ther­a­pies

Last year
Cell/Gene Tx
Manufacturing

Biotech ex­ecs urge in­dus­try to sup­port ac­cess to gen­der-af­firm­ing care, as­sist work­ers amid rush of an­ti-LGBTQ bills

Last year
People

Bio­gen share­hold­ers elect biotech ex­ec Su­san Langer to the board af­ter ro­man­tic part­ner de­parts

Last year
People

Ava­lo fails asth­ma PhII with lead can­di­date, shares crater

Last year
R&D

Fi­bro­Gen re­ports third PhI­II fail­ure in two months, this time in id­io­path­ic pul­monary fi­bro­sis

Last year
R&D

Pfiz­er picks GLP-1 tablet win­ner: Danuglipron for PhI­II

Last year
R&D
Pharma

Sh­iono­gi takes an­tibi­ot­ic mak­er un­der its wing in $100M cash buy­out

Last year
Deals

Ex­clu­sive: The se­cret to de­sign­ing pro­tein drugs with AI? Gen­er­ate be­lieves it's cryo-EM at un­prece­dent­ed scale

Last year
R&D
AI

Sagimet Bio­sciences files again for an IPO af­ter re­leas­ing NASH da­ta

Last year
Financing
Startups

No­vo Nordisk's oral semaglu­tide on par with in­jectable ver­sion in weight loss and safe­ty

Last year
R&D

Moon­Lake's PhII da­ta on skin dis­ease set it up against Cosen­tyx, UCB and oth­ers in IL-17 field

Last year
R&D

Eli Lil­ly's tirzepatide is the king of the GLP-1s, but oth­er op­tions are com­ing

Last year
Pharma

Sarep­ta's Duchenne gene ther­a­py wins OK; FDA spurns NASH drug; Eli Lil­ly buys DICE for $2.4B; The new an­titrust ...

Last year
Weekly

Ver­tex's cell ther­a­py gives ear­ly hope for wean­ing some type 1 di­a­betes pa­tients from in­sulin

Last year
R&D

CHMP rec­om­mends Ab­b­Vie's mi­graine drug, GSK's ane­mia treat­ment

Last year
Pharma

FDA is­sues draft guid­ance for clin­i­cal re­search in­to psy­che­delics

Last year
Discovery
Pharma

Jazz sues FDA, HHS over ri­val nar­colep­sy drug ap­proval

Last year
Pharma
Law

Vi­iV grows HIV pre­ven­tion cam­paign with new in­flu­encers, in­clud­ing ac­tor Taye Dig­gs

Last year
Pharma
Marketing

Medicare spells out what the new Alzheimer's drug reg­istries will col­lect

Last year
Pharma

FDA's Pe­ter Marks over­rode re­view­ers’ call to re­ject Sarep­ta’s new Duchenne gene ther­a­py

2 years ago
Cell/Gene Tx
FDA+

Sarep­ta's gene ther­a­py to be man­u­fac­tured at Catal­ent plant with 'op­er­a­tional chal­lenges' this spring

2 years ago
Cell/Gene Tx
Manufacturing

On­colyt­ic virus start­up Ca­li­di se­cures $25M to­ward Se­ries B round

2 years ago
Financing
First page Previous page 321322323324325326327 Next page Last page
A service from the Financial Times